This episode explores the advancements and challenges in quantum computing and AI-driven drug discovery. Against the backdrop of Google's latest quantum chip announcement, the discussion delves into the complexities of quantum computing, explaining the concept of qubits and the hurdles in scaling up the technology for commercial applications. More significantly, the conversation pivots to the burgeoning field of AI in drug discovery, highlighting the potential of AI to drastically reduce the time and cost of bringing new drugs to market. For instance, the partnership between Relation Therapeutics and GlaxoSmithKline is presented as a significant development in this space. The interview also touches upon the potential bottlenecks in the drug development process, such as regulatory hurdles and the need for human trials, and how AI might address these challenges. In contrast to the hype surrounding quantum computing, the guest emphasizes the current limitations and the potential for AI to overtake some of its projected applications. Ultimately, the episode suggests that while both technologies hold immense promise, their impact and timelines remain uncertain, with AI currently showing more immediate commercial viability in drug development.
